Published in Cancer on June 01, 2004
MRI Guided Transurethral HIFU for Various Prostate Diseases (HIFU-PRO) | NCT03350529
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology (2007) 2.28
Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol (2015) 1.80
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Comprehensive microRNA Profiling of Prostate Cancer. J Cancer (2013) 1.53
Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev (2009) 1.51
Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest (2010) 1.48
Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol (2006) 1.42
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res (2010) 1.09
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol (2012) 1.05
Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Cancer (2012) 1.00
Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines. Int J Mol Med (2012) 0.98
ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology (2010) 0.97
A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. Prostate Cancer Prostatic Dis (2013) 0.95
Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel. Mol Cancer (2007) 0.87
Next generation patient-derived prostate cancer xenograft models. Asian J Androl (2014) 0.85
Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different? Int J Mol Sci (2013) 0.85
Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer (2012) 0.84
Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. J Cell Biochem (2014) 0.84
Re-evaluating the concept of "dominant/index tumor nodule" in multifocal prostate cancer. Virchows Arch (2014) 0.84
Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment. BMC Cancer (2014) 0.83
Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol (2009) 0.83
Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. J Urol (2016) 0.83
ETS rearrangements in prostate cancer. Asian J Androl (2012) 0.82
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer. PLoS One (2015) 0.82
Parameters predicting postoperative unilateral disease in patients with unilateral prostate cancer in diagnostic biopsy: a rationale for selecting hemiablative focal therapy candidates. Can Urol Assoc J (2013) 0.79
Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6. PLoS One (2014) 0.79
Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. Int J Cancer (2016) 0.78
Magnetic Resonance Image-Guided Focal Prostate Ablation. Semin Intervent Radiol (2016) 0.77
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics (Basel) (2016) 0.77
Focal therapy, differential therapy, and radiation treatment for prostate cancer. Adv Urol (2012) 0.77
Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Mod Pathol (2016) 0.77
Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol (2017) 0.75
Focal low-dose rate brachytherapy for the treatment of prostate cancer. Cancer Manag Res (2013) 0.75
A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity. BMC Med Genomics (2016) 0.75
When Prostate Cancer Circulates in the Bloodstream. Diagnostics (Basel) (2015) 0.75
Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomy. Oncol Lett (2014) 0.75
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. BMC Cancer (2017) 0.75
MRI-guided biopsies and minimally invasive therapy for prostate cancer. Indian J Urol (2015) 0.75
Assessment of apparent diffusion coefficient values as predictor of aggressiveness in peripheral zone prostate cancer: comparison with Gleason score. ISRN Radiol (2014) 0.75
Focal therapy for prostate cancer - where are we in 2011? Ther Adv Urol (2011) 0.75
Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight. World J Methodol (2016) 0.75
Tumour heterogeneity poses a significant challenge to cancer biomarker research. Br J Cancer (2017) 0.75
Total intraglandular and index tumor volumes predict biochemical recurrence in prostate cancer. Virchows Arch (2016) 0.75
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
Estimation of impact of American College of Radiology recommendations on CT colonography reporting for resection of high-risk adenoma findings. Am J Gastroenterol (2009) 3.18
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18
Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol (2007) 2.17
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol (2005) 2.14
Feasibility of omitting cortical renorrhaphy during robot-assisted partial nephrectomy: a matched analysis. J Endourol (2015) 2.05
Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol (2013) 2.00
OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol (2004) 1.99
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater (2012) 1.86
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res (2011) 1.80
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol (2010) 1.79
Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev (2012) 1.73
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU Int (2009) 1.71
Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol (2003) 1.70
Training postgraduate urologists in laparoscopic surgery: the current challenge. J Urol (2002) 1.64
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol (2008) 1.64
Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res (2005) 1.63
Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res (2006) 1.61
Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol (2010) 1.61
Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol (2008) 1.60
Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst (2009) 1.59
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. Anal Bioanal Chem (2010) 1.58
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol (2004) 1.53
Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol (2007) 1.53
The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Hum Pathol (2007) 1.53
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. Hum Pathol (2007) 1.52
Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol (2010) 1.51
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics (2008) 1.49
Independent influence of dietary protein on markers of kidney function and disease in obesity. Kidney Int (2010) 1.48
Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem (2010) 1.48
Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol (2013) 1.48
Sclerosing Sertoli cell tumor of the testis: a clinicopathologic study of 20 cases. Am J Surg Pathol (2014) 1.46
Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol (2009) 1.46
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol (2007) 1.45
Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol (2012) 1.43
2009 update on the classification of renal epithelial tumors in adults. Int J Urol (2009) 1.43
Endoloop-assisted laparoscopic partial nephrectomy. J Endourol (2002) 1.42
Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases. Am J Surg Pathol (2013) 1.42
Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol (2010) 1.41
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol (2007) 1.39
Examining the relationship between operative time and hospitalization time in minimally invasive and open urologic procedures. J Endourol (2014) 1.39
Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch (2007) 1.39
Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases. Am J Surg Pathol (2006) 1.39
Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int (2008) 1.36
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Nondestructive, histologically compatible tissue imaging by desorption electrospray ionization mass spectrometry. Chembiochem (2011) 1.34
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer (2010) 1.34
OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res (2004) 1.34
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy. Biomaterials (2010) 1.33
Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol (2002) 1.31
Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol (2006) 1.31
Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol (2006) 1.29